Research programme: muscarinic M4 receptor agonists - BanyuAlternative Names: Muscarinic M4 receptor agonists research programme - Banyu
Latest Information Update: 05 Oct 2006
At a glance
- Originator Banyu
- Mechanism of Action Muscarinic M4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 04 Oct 2006 Discontinued - Preclinical for Pain in Japan (unspecified route)
- 23 Apr 2001 Preclinical development for Pain in Japan (Unknown route)